← Issue №19/ week of Nov 8, 2026/Esophagus/Reflux

Leptomeningeal carcinomatosis arising from esophageal cancer: a systematic review of the literature.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Esophagus/Reflux systematic review · n=43 · Nov 2, 2026 · Diseases of the Esophagus · IF 2.5

Leptomeningeal carcinomatosis arising from esophageal cancer: a systematic review of the literature.

New evidenceesophageal cancersystematic reviewepidemiologybiomarker
Clinical takeawayConsider individualized CNS-directed therapy (radiotherapy or intrathecal therapy) in selected patients with leptomeningeal disease from esophageal cancer, as rare long-term survival is reported. Prioritize early recognition and palliative care given the poor prognosis.
What it foundMedian survival in leptomeningeal carcinomatosis (LMC) from esophageal cancer is 1.1 months, with 3 patients achieving 12, 14, and 19 months survival after individualized CNS-directed therapy.
ContextConfirms the rarity, heterogeneity of presentation, and aggressiveness of LMC from esophageal cancer, previously only described in case reports and small series. Highlights the potential benefit of individualized CNS-directed therapy in a subset of patients.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mylonakis A … Schizas D · Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus · IF 2.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues